MDA Interim / Novartis AG / MDA / TDI / Biogen Idec / ALS TDI / /
Currency
USD / / /
Event
FDA Phase / Business Partnership / /
Facility
Massachusetts General Hospital / FOR IMMEDIATE RELEASE The ALS Therapy Development Institute / About ALS Therapy Development Institute / ALS Therapy Development Institute / /
IndustryTerm
biotechnology / biotechnology institute / health care services / non-profit / /
MedicalCondition
motor neuron diseases / Lou Gehrig’s disease / disease / several disease / progressive neuromuscular diseases / ALS / neuron disease / amyotrophic lateral sclerosis / multiple sclerosis / /
Organization
RGK Foundation / Muscular Dystrophy Association / ALS Therapy Development Institute / Massachusetts General Hospital / Neurology Clinical Trials Unit / Neurology Clinical Trials Unit at Massachusetts General Hospital / /
Person
Valerie Cwik / Steve Perrin / Merit Cudkowicz / Lou Gehrig / Robert A. Goldstein / / /
Position
CEO / Director / President and Medical Director / CEO Investor Conference / /
Media Contact: Robert A. Goldstein, ALS TDI, [removed], [removed]FOR IMMEDIATE RELEASE The ALS Therapy Development Institute to Launch Phase II Clinical Trial on TDI 132 in ALS Patients CAMBRIDGE, MA – Feb